Catalog No.
Product Name
Application
Product Information
Citations
-
SGLT2 inhibitor
Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.- Tingting Ding, .et al. , J Diabetes Complications, 2024, Dec 9;39(2):108930 PMID: 39673870
- David Papadopoli, .et al. , Neoplasia, 2021, Apr;23(4):391-399 PMID: 33784591
- Neil Tanday, .et al. , Biochem Pharmacol, 2020, Jul;177:114009 PMID: 32360307
- Subramaniam M, .et al. , Am J Physiol Regul Integr Comp Physiol, 2019, Nov 20 PMID: 31746628
- Marina Subramaniam, .et al. , Physiol Rep, 2019, May; 7(9): e14090 PMID: 31062524
- Angelopoulou A, .et al. , AAPS PharmSciTech, 2018, Feb;19(2):621-633 PMID: 8924948
- Phloretin inhibits the active transport of glucose into cells by SGLT1 and SGLT2, though the inhibition is weaker than by its glycoside phlorizin.
- Subramaniam M, .et al. , Am J Physiol Regul Integr Comp Physiol, 2019, Nov 20 PMID: 31746628
-
SGLT1/SGLT2 inhibitor
Phlorizin is a competitive inhibitor of SGLT1 and SGLT2; this reduces renal glucose transport, lowering the amount of glucose in the blood.- Subramaniam M, .et al. , Am J Physiol Regul Integr Comp Physiol, 2019, Nov 20 PMID: 31746628
-
SGLT2 Inhibitor
Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2).- Ming-Jer Hsieh, .et al. , Naunyn Schmiedebergs Arch Pharmacol, 2025, Apr 30 PMID: 40304747
- Courtney Sakolish, .et al. , Biomedicines, 2025, 13(3), 563
- Jing Zhou, .et al. , Exp Mol Med, 2022, Nov; 54(11): 2007-2021 PMID: 36385558
- David Papadopoli, .et al. , Neoplasia, 2021, Apr;23(4):391-399 PMID: 33784591
- Angelopoulou A, .et al. , Nanomedicine, 2018, Oct;13(19):2435-2454 PMID: 30311542
-
SGLT2 inhibitor
PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2. - Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes.
- Danubia Silva Dos Santos, .et al. , Sci Rep, 2023, May 29;13(1):8689 PMID: 37248416
- Simone A Melander, .et al. , Eur J Pharmacol, 2023, Jan 5;938:175397 PMID: 36414113
- Yu-Jung Heo, .et al. , Biomedicines, 2022, Apr 29;10(5):1032 PMID: 35625768
- Nami Lee, .et al. , J Immunol Res, 2021, Jun 2;2021:9944880 PMID: 34124273
- CN Koyani, .et al. , Pharmacol Res, 2020, May 17;158:104870 PMID: 32434052
-
SGLT2 inhibitor
Tofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. -
SGLT1/SGLT2 inhibitor
Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor. -
SGLT2 Inhibitor
Luseogliflozin is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM). -
SGLT2 inhibitor
Ipragliflozin is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. -
SGLT2 inhibitor
Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney. -
SGLT2 inhibitor
Canagliflozin hemihydrate is the hemihydrate form of canagliflozin, which is a SGLT2 inhibitor with IC50 of 2.2 nM for hSGLT2 in a cell-free assay, exhibits 413-fold selectivity over hSGLT1.- Wafaa N Albalawy, .et al. , Am J Physiol Renal Physiol, 2024, Jun 1;326(6):F1041-F1053 PMID: 38660713
-
SGLT2 inhibitor
Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. -
SGLT2 inhibitor
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2. -
SGLT inhibitor
Ertugliflozin pidolate belongs to the class of potent and selective inhibitors of the sodium-dependent glucose cotransporters (SGLT), more specifically the type 2 which is responsible for about 90% of the glucose reabsorption from glomerulus. -
SGLT2 inhibitor
Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor. -
SGLT inhibitor
SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively. -
SGLT2 inhibitor
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity. -
SGLT2 inhibitor
Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. -
SGLT1 inhibitor
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. -
HIV-1 Entry Inhibitor
Trilobatin is a natural sweetener extracted from Lithocarpus polystachyus Rehd, functioning primarily as an HIV-1 entry inhibitor by targeting the HIV-1 Gp41 envelope protein. It demonstrates neuroprotective effects and acts as a selective SGLT1/2 inhibitor, promoting the proliferation of human hepatoblastoma cells. Trilobatin is valuable for research involving HIV-1 entry mechanisms and potential therapeutic applications in hepatoblastoma and neuroprotection studies. -
Cytochrome P450 Inhibitor
Kushenol K is a flavonoid antioxidant derived from the roots of Sophora flavescens, functioning as a selective inhibitor of cytochrome P450 3A4 (CYP3A4) with a Ki value of 1.35 μM. This compound exhibits weak antiviral activity against herpes simplex virus type 2 (HSV-2) with an EC50 of 147 μM. Additionally, Kushenol K inhibits sodium-glucose co-transporters SGLT1 and SGLT2, making it relevant for research in metabolic disorders and viral infections. -
Adenosine Receptor Antagonist
Swertisin is an adenosine A1 receptor antagonist with additional SGLT2 inhibitory activity. This compound exhibits various biological functions, including anti-diabetic and antioxidant properties, as well as the ability to inhibit hepatitis B virus (HBV). Research has demonstrated that Swertisin can enhance cognitive function and alleviate memory impairments in murine models, making it a valuable tool for studies in diabetes, neuroprotection, and viral infections. -
Active Metabolite of T-1095
T-1095A is the active metabolite of T-1095, functioning as a sodium-glucose cotransporter (SGLT) inhibitor. This compound demonstrates significant biological activity in the regulation of glucose reabsorption in the renal system and is primarily utilized in research related to diabetes and metabolic disorders. Its mechanism of action aids in the investigation of glucose homeostasis and associated therapeutic strategies. -
SGLT2 Inhibitor
WAY-123783 is a selective and orally active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor. It effectively enhances urinary glucose excretion while simultaneously lowering blood glucose levels in db/db mice, with an ED50 of 9.85 mg/kg. This compound is valuable for research in metabolic diseases, particularly diabetes, facilitating studies on glucose regulation and potential therapeutic interventions. -
SGLT2 Inhibitor
SGLT2-IN-1 is a selective inhibitor of the sodium-dependent glucose cotransporter SGLT2, exhibiting an IC50 of 33 nM in CHO cells transfected with human SGLT2. This compound demonstrates selectivity for SGLT2 over SGLT1, making it a valuable tool for research in glucose homeostasis and metabolic disorders. Additionally, SGLT2-IN-1 serves as an active metabolite of dapagliflozin, contributing to studies focused on diabetes and its associated complications. -
SGLT2 Inhibitor
Henagliflozin is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 value of 2.38 nM for human SGLT2, exhibiting minimal activity against SGLT1 with an IC50 of 4324 nM. This compound is instrumental in diabetes research, facilitating studies on glucose homeostasis and potential therapeutic strategies for diabetic conditions. Its high selectivity and potency make it a valuable tool for investigating the physiological and pharmacological roles of SGLT2 in metabolic disorders. -
Stable Isotope
Empagliflozin-d4 is a deuterium-labeled derivative of Empagliflozin, a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor. With an IC50 of 3.1 nM for human SGLT-2, this stable isotope is utilized primarily in pharmacokinetic studies and metabolic research. Its labeling facilitates the investigation of drug metabolism and the tracking of pharmacological effects in biological systems. -
SGLT-2 Inhibitor
Enavogliflozin is a highly selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor that exhibits potent antidiabetic activity. By inhibiting SGLT-2, Enavogliflozin reduces glucose reabsorption in the kidneys, promoting increased glucose excretion in urine and thereby lowering blood glucose levels. This compound is primarily employed in research applications focused on diabetes management and cardiovascular health. -
SGLT-2 Inhibitor
Tianagliflozin is a selective inhibitor of sodium/glucose cotransporter 2 (SGLT-2), offering potential therapeutic benefit in the management of type 2 diabetes mellitus. By inhibiting SGLT-2, Tianagliflozin promotes the excretion of glucose through the kidneys, thereby lowering blood glucose levels. This compound is of interest in research focused on innovative treatments for glycemic control and metabolic regulation in diabetic patients. -
SGLT2 Inhibitor
Remogliflozin etabonate is a selective inhibitor of the sodium glucose cotransporter 2 (SGLT2), exhibiting Ki values of 1.95 μM for human SGLT2, 2.14 μM for rat SGLT2, 43.1 μM for human SGLT1, and 8.57 μM for rat SGLT1. As a prodrug derived from benzylpyrazole glucoside, it is metabolized into its active form, Remogliflozin, in vivo. This compound demonstrates significant antidiabetic activity in rodent models, making it a valuable tool for research into glucose regulation and diabetes therapies. -
Stable Isotope
Dapagliflozin-d5 is a deuterated form of Dapagliflozin, a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). This stable isotope is utilized in metabolic studies and pharmacokinetic research to trace the absorption and distribution of Dapagliflozin in biological systems. Its application in advanced research provides insights into the drug's mechanism and efficacy in managing diabetes. -
Stable Isotope
Canagliflozin-d4 is a deuterium-labeled derivative of Canagliflozin, a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). This stable isotope is primarily utilized in pharmacokinetic studies and metabolic research to trace and quantify the pharmacological fate of Canagliflozin in biological systems. The presence of deuterium allows for enhanced detection and analysis, facilitating investigations into glucose homeostasis and associated therapeutic applications in diabetes management. -
SGLT2 Inhibitor
Sergliflozin etabonate is a potent and orally active sodium-glucose cotransporter 2 (SGLT2) inhibitor. It exhibits significant antidiabetic and antihyperglycemic effects, as evidenced by its ability to markedly reduce non-fasting blood glucose levels in diabetic mouse models. This compound is primarily utilized in diabetes research to explore therapeutic strategies for glucose management and metabolic regulation. -
SGLT1/SGLT2 Inhibitor
SGLT1/2-IN-1 is a dual inhibitor of SGLT1 and SGLT2, designed to effectively modulate glucose transport mechanisms. This compound exhibits significant biological activity in reducing glucose reabsorption in the kidneys and intestines, making it a valuable tool for research in diabetes and metabolic disorders. Its applications extend to investigating the role of sodium-glucose transporters in glucose homeostasis and potential therapeutic interventions for hyperglycemia. -
SGLT2 Inhibitor
Luseogliflozin hydrate is a selective and potent second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor, exhibiting an IC50 value of 2.26 nM. This compound is primarily utilized in research focused on type 2 diabetes mellitus (T2DM), where its ability to inhibit SGLT2 facilitates the reduction of glucose reabsorption in the kidneys, thereby lowering blood glucose levels. -
SGLT-2 Inhibitor
Rongliflozin is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2), which plays a crucial role in glucose reabsorption in the kidneys. This compound exhibits significant biological activity in the regulation of glucose metabolism and has potential applications in the treatment of type 2 diabetes mellitus (T2DM). Research with Rongliflozin can further elucidate its therapeutic effects and mechanisms of action in managing glycemic control. -
SGLT Inhibitor
rel-Licogliflozin is a sodium glucose cotransporter (SGLT) inhibitor, specifically targeting SGLT1 and SGLT2. This compound demonstrates significant biological activity in glucose transport modulation, making it valuable for research into diabetes and other metabolic disorders. Its role in disrupting glucose reabsorption in the kidneys has potential applications in developing therapeutic strategies for hyperglycemia management. -
SGLT-2 Inhibitor
Atigliflozin is a selective sodium-glucose cotransporter 2 (SGLT-2) inhibitor, displaying IC50 values of 10 nM for hSGLT-2 and 8.2 μM for hSGLT-1. This compound is effective in lowering blood glucose levels and enhancing impaired oral glucose tolerance. Atigliflozin is utilized in research related to type II diabetes mellitus, contributing to the understanding of glucose regulation and potential therapeutic interventions. -
SGLT Inhibitor
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that exhibits significant antidiabetic activity. This compound effectively reduces renal glucose reabsorption, leading to increased glycosuria, which in turn lowers blood glucose and insulin levels. Velagliflozin proline is primarily utilized in research focused on diabetes management and related metabolic disorders. -
SGLT Inhibitor
SGLT1/2-IN-2 is a potent dual inhibitor targeting sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2), with IC50 values of 96 nM and 1.3 nM, respectively. This compound effectively regulates glucose absorption and reabsorption in the kidneys, making it a valuable tool in diabetes research. Its dual inhibitory action offers significant potential in studying glucose homeostasis and developing therapies for metabolic disorders. -
SGLT1/2 Inhibitor
SGLT1/2-IN-8 is a potent dual inhibitor of SGLT1 and SGLT2, exhibiting IC50 values of 4 nM and 1 nM, respectively. This compound demonstrates significant anti-hyperglycemic effects, making it a valuable tool for research in diabetes and glucose regulation. Its oral bioavailability supports its potential in in vivo studies aimed at exploring metabolic disorders. -
Stable Isotope
Empagliflozin-d8 is a deuterium-labeled derivative of Empagliflozin, a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor. With an IC50 of 3.1 nM for human SGLT-2, this compound exhibits significant biological activity in glucose regulation and is utilized in diabetes research. Its stable isotope labeling enables enhanced analytical sensitivity and specificity in pharmacokinetic studies and metabolic profiling.
